AUTOLUS
LIVE

Serial Number

79380366

Owner

Autolus Limited

Attorney

Rebecca Liebowitz

Filing Date

Sep 5, 2023

Add to watchlist:

No watchlists yet
View on USPTO

AUTOLUS Trademark

Serial Number: 79380366 • Registration: 7435787

AUTOLUS is a trademark filed by Autolus Limited on September 5, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Autolus Limited (7 trademarks)

The MediaWorks

Entity Type: 99

Trademark Details

Filing Date

September 5, 2023

Registration Date

July 9, 2024

Published for Opposition

April 23, 2024

Goods & Services

Custom manufacture of therapeutic drugs, namely, cell therapies, cancer therapies and cancer vaccines

Medical and veterinary preparations for therapeutic purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for cell therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for gene therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for cancer therapies for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; cells for medical or clinical use, namely, cells featuring chimeric antigen receptors (CAR) and therapeutic preparations thereof for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; antibodies for medical purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors, namely, culture media for cultivating and augmentation of human and animal cells; preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes; vaccines

Medical services; veterinary services; medical and veterinary services in the nature of extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes, namely, medical services relating to the removal, treatment and processing of human and animal cells; medical and veterinary services in the nature of reinsertion of cells into human and animal patients; providing medical advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies and cancer vaccines

Scientific and technological services and research and design relating thereto, namely, medical research, scientific research, analysis and testing in the field of human and animal cell, gene and cancer therapies, pharmaceutical product development, research and development of new products; industrial analysis and research services in the field of cell, gene and cancer therapies; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccines, including personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 22, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 4, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 4, 2025 OPNR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 1, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 1, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 1, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 1, 2025 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 10, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 20, 2024 FICS
FINAL DISPOSITION PROCESSED
Dec 20, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 10, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 9, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 9, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 23, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 23, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 3, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 16, 2024 CNSA
REFUSAL PROCESSED BY IB
Mar 5, 2024 RFNT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 1, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 29, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 29, 2024 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 14, 2024 RFCS
REFUSAL PROCESSED BY MPU
Feb 14, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 26, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jan 25, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 25, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 14, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 10, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 5, 2023 REPR